Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Lane reported serving on speaker and advisory panels for Novo Nordisk A/S and Insulet Corp; as an author for Novo Nordisk A/S; and receiving research funding from Novo Nordisk A/S, Insulet, and Lilly. Dr Bailey reported serving as a consultant for AstraZeneca, Bayer Healthcare, BD Biosciences, Medtronic, Novo Nordisk A/S, Sanofi US, Calibri, and Lilly; receiving research support from Abbott, Ambra, Ascensia, Boehringer Ingelheim, BD Biosciences, Calibra, Companion Medical, Dexcom, Elcelyx, Glysens, Janssen, Lexicon, Lilly, Medtronic, Novo Nordisk, Sanofi, Senseonics, Versartis, and Xeris; and serving as a speaker for Abbott, Insulet, Medtronic, Lilly, Novo Nordisk, and Sanofi. Dr Gerety reported serving as a consultant to Dexcom; receiving research support from Boehringer Ingelheim, Lexicon, Novo Nordisk A/S, and Locemia Solutions; and participating in speakers’ panels for AstraZeneca, Boehringer Ingelheim, Dexcom, Lilly, Merck, Novo Nordisk A/S, and Janssen.

中文翻译：

---

疗养院的抗精神病药物处方

利益冲突披露：作者已完成并提交了 ICMJE 潜在利益冲突披露表。Lane 博士曾在 Novo Nordisk A/S 和 Insulet Corp 的演讲者和顾问小组任职；作为 Novo Nordisk A/S 的作者；并获得 Novo Nordisk A/S、Insulet 和 Lilly 的研究资助。Bailey 博士报告曾担任 AstraZeneca、Bayer Healthcare、BD Biosciences、Medtronic、Novo Nordisk A/S、Sanofi US、Calibri 和 Lilly 的顾问；获得雅培、Ambra、Ascensia、勃林格殷格翰、BD Biosciences、Calibra、Companion Medical、Dexcom、Elcelyx、Glysens、Janssen、Lexicon、礼来、美敦力、诺和诺德、赛诺菲、Senseonics、Versartis 和 Xeris 的研究支持；并担任雅培、Insulet、美敦力、礼来、诺和诺德和赛诺菲的发言人。Gerety 博士报告称曾担任 Dexcom 的顾问；获得勃林格殷格翰、Lexicon、Novo Nordisk A/S 和 Locemia Solutions 的研究支持；并参加阿斯利康、勃林格殷格翰、Dexcom、礼来、默克、Novo Nordisk A/S 和 Janssen 的演讲者小组讨论。